Outcome of the 32nd Annual General Meeting of the Company.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Oxygenta Pharmaceutical Ltd held its 32nd AGM on September 19, 2025 via video conferencing, with 61 members attending. A total of 14 resolutions were passed with overwhelming majority (approximately 99.99% in favour), representing 2.55 crore shares voted. Key items included adoption of FY25 audited financial statements, re-appointment and appointment of multiple directors (including whole-time, non-executive and independent directors), and ratification of the Cost Auditor's remuneration. Two important financial resolutions approved were the borrowing power up to Rs. 200 crore and permission to create mortgage/charge on company assets. Members also approved material related party transactions (sale/purchase and loan/guarantee) with the holding company, Virupaksha Organics Limited.
All resolutions passed with near-unanimous support, indicating strong shareholder alignment with management. The enhanced borrowing limit of Rs. 200 crore and related party transaction approvals with the holding company Virupaksha Organics signal continued post-acquisition integration and potential expansion plans, which could drive future growth but also increases financial leverage capacity.